Oncology News | pharmaphorum

News

NICE backs NHS use for Astellas' Xospata after rethink

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia

News

FDA experts okay GSK's multiple myeloma drug despite safety ...

GlaxoSmithKline’s potential first-in-class multiple myeloma drug belantamab mafodotin has taken a step closer to US approval after unanimous backing from a panel of expert advisers convened

News

Ex-Taris CEO Tony Kingsley claims tenure as Scholar Rock's n...

After more than eight years at the helm of US biotech Scholar Rock, Nagesh Mahanthappa is standing down as CEO, to be replaced by biopharma industry veteran Tony Kingsley.<

News

Roche signs $1.7bn deal with Blueprint around cancer drug pr...

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations.

News

FDA reviewer warns of eye trouble with GSK’s myeloma ADC

GlaxoSmithKline heads for an FDA advisory committee meeting this week for belantamab mafodotin – its much-touted treatment for multiple myeloma – with a question about safety h

News

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery.

NICE backs NHS use for Astellas' Xospata after rethink

FDA experts okay GSK's multiple myeloma drug despite safety ...

Ex-Taris CEO Tony Kingsley claims tenure as Scholar Rock's n...

Roche signs $1.7bn deal with Blueprint around cancer drug pr...

FDA reviewer warns of eye trouble with GSK’s myeloma ADC

Roche's Tecentriq cocktail fails in newly-diagnosed ovarian ...

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks